National study finds reduced glaucoma risk in patients who take statins

October 1, 2012

People who take statins to reduce their risk of cardiovascular disease are less likely to be diagnosed with the most common form of glaucoma, according to a nationwide study of more than 300,000 patients. A University of Michigan School of Medicine research team, directed by Joshua Stein, MD, MS, found that the risk for glaucoma was reduced by eight percent in patients who took statins continuously for two years, compared with patients who did not take statins. The study, the largest to date on the topic, is published in the October issue of Ophthalmology, the journal of the American Academy of Ophthalmology.

Dr. Stein's study was sparked by growing evidence that statin use may protect the optic nerve and retinal , structures that are essential to good vision and are damaged by . His team used healthcare claims data for a diverse population of Americans aged 60 and older who took statins to control high blood levels of unhealthy fats, a condition known as hyperlipidemia, between 2001 and 2009, The researchers assessed patients' risk for open-angle glaucoma (OAG). Unlike earlier studies, their analysis adjusted for patients who also had diabetes and/or hypertension to prevent distortion of the results.

Several of the study's findings suggest that statin use may be most important before glaucoma is diagnosed, or in the early stages of the disease. Dr. Stein's research may lead to new preventive treatments that could especially benefit groups at increased risk, including African-Americans, Hispanics and those with a family history of glaucoma.

Glaucoma affects more than 2.7 million Americans age 40 and older . If untreated, glaucoma causes vision loss or blindness by damaging the eye's optic nerve. The optic nerve sends signals from the retina—a layer of light-sensitive tissue at the back of the eye—to the brain, where these signals are interpreted as the images we see. Only about half of the people who have glaucoma know it, since symptoms are rarely noticed in the early stages and is very gradual in most cases.

"Statins' apparent ability to reduce glaucoma risk may be due to several factors, including improved blood flow to the and retinal nerve cells and enhanced outflow of the aqueous fluid, which may reduce intraocular pressure," said Dr. Stein. "While more research is needed, we hope our results may contribute to saving the sight of thousands who are predisposed to glaucoma."

Dr. Stein cautioned that the study results apply only to patients with , and that further study is needed to determine whether statins also protect patients who don't have this diagnosis or have other characteristics that differ from the study population.

Explore further: Study focuses on relationship between glaucoma and diabetes, hypertension

Related Stories

Study focuses on relationship between glaucoma and diabetes, hypertension

August 17, 2011
Many Americans suffer from diabetes and hypertension and, according to a study by researchers at the University of Michigan Kellogg Eye Center, these individuals may have an increased risk of developing open-angle glaucoma ...

The cost of glaucoma care: Small group of patients accounts for large part of costs

September 18, 2012
A small subset of patients with open-angle glaucoma (OAG) account for a large proportion of all glaucoma-related charges in the United States, according to new data published by researchers at the University of Michigan Kellogg ...

Study suggests glaucoma screenings are happening too late

September 29, 2011
Glaucoma is the second leading cause of blindness worldwide. Although it can be treated, new research shows Canadians may not be doing enough to protect themselves. According to a new study by Lawson Health Research Institute's ...

Recommended for you

Scientists engineer drug delivery device that treats glaucoma directly inside the eye

November 23, 2017
Glaucoma, which affects over 60 million people worldwide, can seem easy to treat: medicated eye drops can be used to ease the buildup of fluid in the eye that underlies the condition. If glaucoma is caught early, eye drops ...

Research reveals biological mechanism of a leading cause of childhood blindness

November 16, 2017
Scientists at the Virginia Tech Carilion Research Institute (VTCRI) have revealed the pathology of cells and structures stricken by optic nerve hypoplasia, a leading cause of childhood blindness in developed nations.

Genetic treatment for blindness may soon be reality

November 11, 2017
Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting ...

Study finds donor corneas can be safely preserved for longer period

November 10, 2017
Results from a large, national clinical trial show that corneal donor tissue can be safely stored for 11 days without negatively impacting the success of transplantation surgery to restore vision in people with diseases of ...

Exploring the genetics of glaucoma and retinal development

November 10, 2017
Guillermo Oliver, PhD, the Thomas D. Spies Professor of Lymphatic Metabolism, recently published two studies related to the eye, one on retinal formation and the other on the genetics behind glaucoma.

Scientists discover potential treatment to stop glaucoma in its tracks

November 6, 2017
Vision scientists at the University of California, Berkeley, and the University of Toronto have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.